Lens delivery system cartridge

Information

  • Patent Grant
  • 8894664
  • Patent Number
    8,894,664
  • Date Filed
    Friday, February 6, 2009
    15 years ago
  • Date Issued
    Tuesday, November 25, 2014
    9 years ago
Abstract
A cartridge for an IOL delivery system that has an injector tip geometry designed to reduce stresses at the incision wound edges generated during insertion of an IOL into an eye is disclosed. The injector tip geometry includes a tubular nozzle having a modified elliptical cross section. The injector tip geometry reduces stresses generated reduce the likelihood of tearing or overstretching the wound during cartridge tip insertion and residence time in the wound while the lens is being delivered into the eye.
Description
BACKGROUND OF THE INVENTION

The human eye in its simplest terms functions to provide vision by transmitting and refracting light through a clear outer portion called the cornea, and further focusing the image by way of the lens onto the retina at the back of the eye. The quality of the focused image depends on many factors including the size, shape and length of the eye, and the shape and transparency of the cornea and lens.


When trauma, age or disease cause the lens to become less transparent, vision deteriorates because of the diminished light which can be transmitted to the retina. This deficiency in the lens of the eye is medically known as a cataract. The treatment for this condition is surgical removal of the lens and implantation of an artificial lens or IOL.


While early IOLs were made from hard plastic, such as polymethylmethacrylate (PMMA), soft, foldable IOLs made from silicone, soft acrylics and hydrogels have become increasingly popular because of the ability to fold or roll these soft lenses and insert them through a smaller incision. Several methods of rolling or folding the lenses are used. One popular method is an injector cartridge that folds the lenses and provides a relatively small diameter lumen through which the lens may be pushed into the eye, usually by a soft tip plunger. The most commonly used injector cartridge design is illustrated in U.S. Pat. No. 4,681,102 (Bartell), and includes a split, longitudinally hinged cartridge. Similar designs are illustrated in U.S. Pat. Nos. 5,494,484 and 5,499,987 (Feingold) and U.S. Pat. Nos. 5,616,148 and 5,620,450 (Eagles, et al.). In an attempt to avoid the claims of U.S. Pat. No. 4,681,102, several solid cartridges have been investigated, see for example U.S. Pat. Nos. 5,275,604 (Rheinish, et al.) and U.S. Pat. No. 5,653,715 (Reich, et al.).


These prior art devices were intended to inject an IOL into the posterior chamber of an aphakic eye through a relatively large (approximately 3.0 mm or larger) incision. Surgical techniques and IOLs have been developed that allow the entire surgical procedure to be performed through much smaller incisions, 2.4 mm and smaller. Such small incisions require that the IOL be compressed very tightly, and that the nozzle used on the injection cartridge have very thin walls. The combination of a tightly compressed lens traveling through a very thin walled nozzle often results in the nozzle splitting during use. In addition, although the surgeon may make the incision a specific size, insertion and manipulation of the cartridge and the lens frequently stresses the incision walls, increasing the size of the incision as well as causing trauma to the surrounding tissue.


Accordingly, a need continues to exist for an intraocular lens injection cartridge capable of injection an IOL through a relatively small incision with reduced trauma to the tissue.


BRIEF SUMMARY OF THE INVENTION

The present invention improves upon the prior art by providing a cartridge for an IOL delivery system that has a injector tip geometry designed to reduce applied stresses on the incision during insertion of the cartridge tip through the wound to reduce the likelihood of tearing or overstretching the wound during cartridge tip insertion and residence time in the wound while the lens is being delivered into the eye.


It is accordingly an objective of the present invention to provide a cartridge for a lens delivery system that has an injector tip geometry designed to reduce stresses on the wound incision.


It is a further objective of the present invention to provide a cartridge for a lens delivery system that reduces post insertion wound trauma.


Other objectives, features and advantages of the present invention will become apparent with reference to the drawings, and the following description of the drawings and claims.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a graph comparing the arc length for a circle, an ellipse and a straight line;



FIG. 2 is a graph illustrating theoretical incision size for various tip sizes; and



FIG. 3 is an enlarged perspective view of the lens delivery system cartridge of the present invention.



FIG. 4 is a graph illustrating a circle used to form a blend radius for forming a modified elliptical cross-sectional shape of an injection tip, where the circle is tangent to both a curve above and below an inflection point and that has a 90 degree tangent line at a point crossing the x-axis.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed to cartridge 10 having a body 11 and tip 12, tip 12 having a geometry designed to reduce stresses generated during insertion of an IOL into an eye. Although any incision size can be used, the dimensions given in the following discussion are based on a 2.0 mm incision or wound in the eye.


The action of inserting a cartridge tip 12 through an incision wound develops stresses at the wound edges that can result in trauma and tearing of the incision. The inventors have discovered that a correlation exists between the degree of wound stresses and cartridge tip geometry. Based on this discovery, the inventors determined that the incision or wound can be modeled as a deformable body having roughly an elliptical outer dimension with a major axis of approximately 2.0 mm and a minor axis of approximately 0.25 mm. In addition, the inventors determined that a cartridge tip 12 nozzle can be modeled as a rigid body with the assumption that no deformation of the tip 12 nozzle occurs during the insertion of an IOL into an eye and that any deformation occurs in the wound. As no actual tissue material properties are available, the material properties of the wound tissue can be modeled using the Arruda-Boyce material model. Assuming that the area of the tip 12 nozzle is larger than the area of the wound, the inventors applied a theoretical load to the inside of the wound to “stretch” the wound large enough to allow the nozzle tip 12 to enter. By lowering the theoretical load until the interior wound margins contact the entire outer peripheral surface of the tip 12, the residual strain, stress, stress distribution and contact pressure can be determined.


One skilled in the art understands that a circle or round cartridge tip has an aspect ratio of 1 because the height and width are equal. However, as the aspect ratio is reduced by shortening the height, the arc length changes which serves to reduce the degree of wound stretching by reducing the applied stresses at the wound edges as shown in FIG. 1. One skilled in the art also understands that a straight line connecting height and width results in the shortest distance between those points and represents the shortest “arc” length possible relative to applied stresses on the wound without creating a negative arc. Negative arc is undesirable because lens damage or undesirable folding can occur when a negative arc or non-curved geometry is used.


The cross-sectional form of an ellipsoid, representing the injection tip 12 geometry, can be analyzed by using the ellipse shape factor. This shape factor ‘ε’ can remain constant to maintain the same form as the tip size is varied from 3.0 mm and below. By varying other parameter values, the form is maintained while reducing the periphery and resultant theoretical incision size as shown in Table 1 below and FIG. 2.



FIG. 4 shows a Cartesian coordinate system 40 having an abscissa axis (interchangeably referred to as “x-axis”) 42 and an ordinate axis (interchangeably referred to as “y-axis”) 44. The Cartesian coordinate system 40 defines a first quadrant (also referred to as quadrant I) 46, a second quadrant (also referred to as quadrant II) 48, a third quadrant (also referred to as quadrant III) 50, and a fourth quadrant (also referred to as quadrant IV) 52.


This shape factor ε, also known as eccentricity, is further discussed below starting with the ellipse equation. A cross section of an ellipsoid in a plane parallel to coordinate axes forms an ellipse. In general, this 2D ellipse can be represented by the following equation:











(

x
-
h

)

2


a
2


+



(

y
-
k

)

2


b
2



=
1

;





Where h, k represent the center of the ellipse, ‘a’ is the major axis and ‘b’ the minor axis. The shape of an ellipse can be represented by its eccentricity, ε, defined as follows:

ε=(1/a)(√{square root over (a2−b2)});

where 0<ε<1. The larger the value of ε is, the larger the ratio of a to b and the more elongated the ellipse becomes. Furthermore, for a given eccentricity value, if we know parameter ‘a’ or ‘b’ then the other parameter can be easily calculated using this equation.For completion, note that parameters ‘a’ and ‘b’ are constrained by the following equation:

c2=a2−b2;

where ‘(±c,0)’ represent the foci of the ellipse. Note that the cross section of the ellipse is modified in the sense that the center of the ellipse is not necessarily at the origin and is allowed to float. For example, FIG. 4 shows ellipse 54 having center 56. FIG.4 shows the center 56 located along the negative portion of the y-axis 44. However, allowing for de-centration of the ellipse leaves a point of inflection 102 (shown in FIG. 4), a sharp feature, when the part of the ellipse lying in quadrant I 46 is revolved around the x-axis 42. To smooth out this point, a blend in radius is used so that the tangent to the point intersecting the x-axis is at 90 degrees. These two features, the decentered ellipse as well as a blend radius 104 constitute the cross section of the modified ellipsoid configuration.


An alternate form to the above ellipse equation can be represented as,

Ax2+Bxy+Cy2+Dx+Ey+F=0;

where B2<4AC and all coefficients are real. This equation can be converted to the first equation by completing squares and obtaining a form that displays the center of the ellipse as well as the lengths of major and minor axes.


Using the above guidelines, these parameters can be calculated. The elliptic curve in quadrant 1 was fitted to a general ellipse and it was found that (h, k)=(0.0,−0.13), and (a, b)=(0.95, 0.72). The eccentricity ε was then calculated to be 0.65. Given this eccentricity, if either of the two axial dimensions of the ellipse is to be changed, then the other can be calculated with the above equation. Generally, the blend radius at the point of inflection can be chosen to be the smallest possible circle that is tangent to both the curve above and below and has a 90 deg. tangent line at the point crossing the x-axis, such as circle 100 of FIG. 4.


An example of the application of the determined minimum arc length, aspect ratio and blend radius described above can be seen in Table 1 below where typical values for each of the variables are shown. The table defines typical modified ellipsoid values as a function of incision size. Incision sizes of 1.0, 2.0 and 3.0 mm are used to demonstrate the relationship when the ArcLength width and Ellipse eccentricity are held constant. Applying these values to cartridge tip designs result in the maximum internal volume relative to the minimum arc length which in combination results in significantly reduced strain at the incision wound edges while minimizing the degree of lens compression and resultant lens injection forces.









TABLE 1







Modified Ellipsoid typical dimensions as a function of Incision size.
















Ellipse


Blend


Incision
Ellipse Major
Ellipse Minor
Eccentricity,
ArcLength
ArcLength/
Radius


Size (mm)
Axis, a (mm)
Axis, b (mm)
ε
(mm)
Width
(mm)





1.0
0.392
0.30
0.65
1.087
1.386
0.2


2.0
0.784
0.60
0.65
2.174
1.386
0.4


3.0
1.176
0.90
0.65
3.261
1.386
0.6









The steps outlined above result in a design for cartridge tip 12 that provides the maximum internal volume relative to the minimum arc length. This combination results in significantly reduced strain at the incision wound edges while minimizing the degree of lens compression and resultant lens injection forces. The invention described within provides injector cartridge 10 or nozzle tip 12 shape that reduces the force required to insert cartridge tip 12 through the wound due to the reduced aspect ratio and arc length. In addition, this curved form facilitates reduced wound trauma and potential for lens damage through elimination of sharp external and internal features or transition points.


While certain embodiments of the present invention have been described above, these descriptions are given for purposes of illustration and explanation. Variations, changes, modifications and departures from the systems and methods disclosed above may be adopted without departure from the scope or spirit of the present invention.

Claims
  • 1. An intraocular lens delivery system cartridge, comprising: a body, anda tubular nozzle connected to the body and projecting distally from the body, the nozzle having a cross-section, the cross-section having a shape defined by: a portion of an ellipse disposed in a first quadrant and a second quadrant of a Cartesian coordinate system, the ellipse having a center that is offset from the origin of the Cartesian coordinate system in a direction along a negative portion of an ordinate axis of the Cartesian coordinate system, the portion of the ellipse defined as a first curve; anda second curve defined as a mirror image of the first curve mirrored about an abscissa axis of the Cartesian coordinate system, the first curve and the second curve forming first and second points at locations where the first curve and the second curve intersect the abscissa axis of the Cartesian coordinate system; andcircular arcs formed at opposing ends of the cross-section proximate the first and second points, each circular arc defined as a portion of a circle joining the first curve and the second curve that is tangent to both the first curve and the second curve and that has a 90 degree tangent line at a point along the abscissa axis crossed by the circular arc.
  • 2. The cartridge of claim 1, wherein the ellipse has an ellipse eccentricity of 0.65.
  • 3. The cartridge of claim 1, wherein a distance defined along the abscissa axis between locations where the circular arcs intersect the abscissa axis defines a width of the cross-section, wherein a portion of the cross-section comprises a portion of one of circular arcs extending from the abscissa axis to the first curve, a portion of the first curve extending between the circular arcs, and a portion of the other of the circular arcs extending from the first curve to the abscissa axis,wherein a length of the portion of the cross-section defines an arc length, andwherein a ratio of the arc length to the width of the cross-section is 1.386.
Parent Case Info

This application claims priority under 35 USC §119 to U.S. provisional application Ser. No. 61/026,805, filed on Feb. 7, 2008. This invention relates to intraocular lenses (IOLs) and more particularly to cartridges for use with devices used to inject IOLs into an eye.

US Referenced Citations (177)
Number Name Date Kind
4198980 Clark Apr 1980 A
4214585 Bailey, Jr. Jul 1980 A
4573998 Mazzocco Mar 1986 A
4600003 Lopez Jul 1986 A
4619657 Keates et al. Oct 1986 A
4681102 Bartell Jul 1987 A
4747404 Jampel et al. May 1988 A
4765329 Cumming et al. Aug 1988 A
4834094 Patton et al. May 1989 A
4836201 Patton et al. Jun 1989 A
4919130 Stoy et al. Apr 1990 A
4934363 Smith et al. Jun 1990 A
4955889 Van Gent Sep 1990 A
4960557 Sorensen Oct 1990 A
4988352 Poley Jan 1991 A
5007913 Dulebohn et al. Apr 1991 A
5026396 Darin Jun 1991 A
5098439 Hill et al. Mar 1992 A
5176686 Poley Jan 1993 A
5190552 Kelman Mar 1993 A
5195526 Michelson Mar 1993 A
5275604 Rheinish et al. Jan 1994 A
5290892 Namdaran et al. Mar 1994 A
5304182 Rheinish et al. Apr 1994 A
5354333 Kammann et al. Oct 1994 A
5397313 Gross Mar 1995 A
5425734 Blake Jun 1995 A
5444183 Gehrs et al. Aug 1995 A
5464396 Barta et al. Nov 1995 A
5468246 Blake Nov 1995 A
5474562 Orchowski et al. Dec 1995 A
5494484 Feingold Feb 1996 A
5496278 Buff Mar 1996 A
5496328 Nakajima et al. Mar 1996 A
5499987 Feingold Mar 1996 A
5571113 McDonald Nov 1996 A
5578042 Cumming Nov 1996 A
5582614 Feingold Dec 1996 A
5607433 Polla et al. Mar 1997 A
5616148 Eagles et al. Apr 1997 A
5620450 Eagles et al. Apr 1997 A
5629577 Polla et al. May 1997 A
5643275 Blake Jul 1997 A
5643276 Zaleski Jul 1997 A
5653715 Reich et al. Aug 1997 A
5653753 Brady et al. Aug 1997 A
5716364 Makker et al. Feb 1998 A
5728102 Feingold et al. Mar 1998 A
5735858 Makker et al. Apr 1998 A
5772666 Feingold et al. Jun 1998 A
5776138 Vidal et al. Jul 1998 A
5800441 Polla et al. Sep 1998 A
5800442 Wolf et al. Sep 1998 A
5803925 Yang et al. Sep 1998 A
5810834 Heyman Sep 1998 A
5820373 Okano et al. Oct 1998 A
5860986 Reich et al. Jan 1999 A
5868752 Makker et al. Feb 1999 A
5873879 Figueroa et al. Feb 1999 A
5876406 Wolf et al. Mar 1999 A
5876407 Makker et al. Mar 1999 A
5891153 Peterson Apr 1999 A
5928245 Wolf et al. Jul 1999 A
5944725 Cicenas et al. Aug 1999 A
5947976 Van Noy et al. Sep 1999 A
6010510 Brown et al. Jan 2000 A
6042587 Polla et al. Mar 2000 A
6056758 Vidal et al. May 2000 A
6083231 Van Noy et al. Jul 2000 A
6140602 Costin Oct 2000 A
6143001 Brown et al. Nov 2000 A
6162229 Feingold et al. Dec 2000 A
6162230 Polla et al. Dec 2000 A
6179843 Weiler Jan 2001 B1
6193683 Ludin et al. Feb 2001 B1
6228094 Erdman May 2001 B1
6241737 Feingold Jun 2001 B1
6254607 Makker et al. Jul 2001 B1
6312433 Butts et al. Nov 2001 B1
6334862 Vidal et al. Jan 2002 B1
6355046 Kikuchi et al. Mar 2002 B2
6387101 Butts et al. May 2002 B1
6398789 Capetan Jun 2002 B1
6406481 Feingold et al. Jun 2002 B2
6423035 Das et al. Jul 2002 B1
6447519 Brady et al. Sep 2002 B1
6468282 Kikuchi et al. Oct 2002 B2
6471708 Green Oct 2002 B2
6491697 Clark et al. Dec 2002 B1
6497708 Cumming Dec 2002 B1
6500181 Portney Dec 2002 B1
6503275 Cumming Jan 2003 B1
6506195 Chambers et al. Jan 2003 B2
6558395 Hjertman et al. May 2003 B2
6592591 Polla et al. Jul 2003 B2
6605093 Blake Aug 2003 B1
6607537 Binder Aug 2003 B1
6635731 Mentak Oct 2003 B2
6666871 Klkuchi et al. Dec 2003 B2
6685740 Figueroa et al. Feb 2004 B2
6899698 Sams May 2005 B2
6899717 Weber et al. May 2005 B2
6923815 Brady et al. Aug 2005 B2
6964648 Talling et al. Nov 2005 B2
6976989 Vincent Dec 2005 B1
7014641 Kobayashi et al. Mar 2006 B2
7037328 Vincent May 2006 B2
7042180 Terry et al. May 2006 B2
7131976 Kobayashi et al. Nov 2006 B2
7156854 Brown et al. Jan 2007 B2
7156855 Oda Jan 2007 B2
7189218 Lichtenberg Mar 2007 B2
7217274 Meyer May 2007 B2
7279006 Vincent Oct 2007 B2
7357426 Bormioli Apr 2008 B2
7422604 Vaquero et al. Sep 2008 B2
7429263 Vaquero et al. Sep 2008 B2
20010007075 Hjertman et al. Jul 2001 A1
20020151904 Feingold et al. Oct 2002 A1
20030033013 Callahan et al. Feb 2003 A1
20030040755 Meyer Feb 2003 A1
20030135221 Sabet Jul 2003 A1
20030139749 Kikuchi et al. Jul 2003 A1
20030212406 Kobayashi et al. Nov 2003 A1
20030212409 Kobayashi et al. Nov 2003 A1
20040024361 Fago et al. Feb 2004 A1
20040054374 Weber et al. Mar 2004 A1
20040087896 Wise et al. May 2004 A1
20040097954 Meyer May 2004 A1
20040097956 Oda May 2004 A1
20040147938 Dusek et al. Jul 2004 A1
20040160575 Ayton et al. Aug 2004 A1
20040199174 Herberger et al. Oct 2004 A1
20040215207 Cumming Oct 2004 A1
20040238392 Peterson et al. Dec 2004 A1
20050049605 Vaquero et al. Mar 2005 A1
20050049606 Vaquero et al. Mar 2005 A1
20050065534 Hohl Mar 2005 A1
20050143750 Vaquero Jun 2005 A1
20050149056 Rathert Jul 2005 A1
20050149057 Rathert Jul 2005 A1
20050203619 Altmann Sep 2005 A1
20050222578 Vaquero Oct 2005 A1
20050222579 Vaquero et al. Oct 2005 A1
20050283164 Wu et al. Dec 2005 A1
20060066962 Drobnik et al. Mar 2006 A1
20060085013 Dusek et al. Apr 2006 A1
20060167466 Dusek Jul 2006 A1
20060184181 Cole et al. Aug 2006 A1
20060200167 Peterson et al. Sep 2006 A1
20060229633 Shepherd Oct 2006 A1
20060229634 Shepherd Oct 2006 A1
20060235429 Lee et al. Oct 2006 A1
20060284581 Mullin et al. Dec 2006 A1
20060287655 Khuray et al. Dec 2006 A1
20070005135 Makker et al. Jan 2007 A1
20070050023 Bessiere et al. Mar 2007 A1
20070060925 Pynson Mar 2007 A1
20070173860 Iwasaki Jul 2007 A1
20070270945 Kobayashi et al. Nov 2007 A1
20080033449 Cole et al. Feb 2008 A1
20080039862 Tran Feb 2008 A1
20080058830 Cole et al. Mar 2008 A1
20080086146 Ishii et al. Apr 2008 A1
20080097459 Kammerlander et al. Apr 2008 A1
20080097461 Boukhny et al. Apr 2008 A1
20080119865 Meunier et al. May 2008 A1
20080200920 Downer Aug 2008 A1
20080200921 Downer Aug 2008 A1
20080221584 Downer Sep 2008 A1
20080221585 Downer Sep 2008 A1
20080255577 Downer Oct 2008 A1
20090043313 Ichinohe et al. Feb 2009 A1
20090112223 Downer Apr 2009 A1
20090171366 Tanaka Jul 2009 A1
20090204123 Downer Aug 2009 A1
20090216244 Pynson Aug 2009 A1
Foreign Referenced Citations (85)
Number Date Country
728443 Jan 2001 AU
101073519 Nov 2007 CN
4301573 Jul 1994 DE
19544119 May 1997 DE
20219445 Mar 2003 DE
0174917 Mar 1986 EP
0270257 Jun 1988 EP
0363213 Apr 1990 EP
0477466 Jun 1996 EP
0858304 Aug 1998 EP
0962195 Dec 1999 EP
1011561 Jun 2000 EP
1075826 Feb 2001 EP
1076408 Feb 2001 EP
1332731 Aug 2003 EP
1360944 Nov 2003 EP
1481652 Dec 2004 EP
1661533 May 2006 EP
1832247 Sep 2007 EP
1849436 Oct 2007 EP
1857076 Nov 2007 EP
1891911 Feb 2008 EP
1941846 Jul 2008 EP
1958593 Aug 2008 EP
1958594 Aug 2008 EP
2062552 May 2009 EP
2820633 Aug 2002 FR
1274949 May 1972 GB
2224214 May 1990 GB
2333460 Jul 1999 GB
1176288 Dec 1989 JP
5-103808 Apr 1993 JP
3664444 Apr 1994 JP
10309294 Nov 1998 JP
10511876 Nov 1998 JP
10512460 Nov 1998 JP
2000025073 Jan 2000 JP
2000-513955 Oct 2000 JP
2003070829 Mar 2003 JP
2003325569 Nov 2003 JP
2005-110924 Apr 2005 JP
2006014962 Jan 2006 JP
2006181269 Jul 2006 JP
2007055057 Mar 2007 JP
2007-307168 Nov 2007 JP
2007-319539 Dec 2007 JP
2138232 Sep 1999 RU
2171100 Jul 2001 RU
2238283 Oct 2004 RU
2242956 Dec 2004 RU
2379010 Jan 2010 RU
1440496 Nov 1988 SU
1706614 Jan 1992 SU
1814870 May 1993 SU
9420027 Sep 1994 WO
9603924 Feb 1996 WO
9610372 Apr 1996 WO
9620662 Jul 1996 WO
9628122 Sep 1996 WO
9629956 Oct 1996 WO
9715253 May 1997 WO
9726841 Jul 1997 WO
9805281 Feb 1998 WO
9812969 Apr 1998 WO
9815244 Apr 1998 WO
9820819 May 1998 WO
0040175 Jul 2000 WO
0062712 Oct 2000 WO
0139701 Jun 2001 WO
02060338 Aug 2002 WO
WO 02 083216 Oct 2002 WO
02100468 Dec 2002 WO
2004091447 Oct 2004 WO
2006007303 Jan 2005 WO
2005018515 Mar 2005 WO
2005020853 Mar 2005 WO
2005023154 Mar 2005 WO
2005102223 Nov 2005 WO
2006059183 Jun 2006 WO
2006070561 Jul 2006 WO
2006080191 Aug 2006 WO
2006113138 Oct 2006 WO
2006113357 Oct 2006 WO
2007037223 Apr 2007 WO
2007080868 Jul 2007 WO
Non-Patent Literature Citations (8)
Entry
Ellipse, by J.B. Calvert, Denver University,website created on May 6, 2002.
International Search Report for PCT/US2009/033401, Publication No. WO2009/100337, 4 pages, dated Jun. 18, 2009.
European Search Report for Application No. 08102185.9, Publication No. EP2002803, Published Dec. 17, 2008, dated Apr. 25, 2008, 3 pages.
PCT International Preliminary Report on Patentability and Written Opinion of the International Searching Authority, International Application No. PCT/2009/033401, dated Aug. 10, 2010, 5 pages.
European Search Report for Application No. 08102172.7, Publication No. 1980219, dated Oct. 15, 2008, 5 pages.
Abstract of article entitled “Implantation of the AcrySof MA30BA lens using the Monarch System” by Barakova D., original article found in Cesk slov Oftalmol, 2002 58(3), at p. 149-152, found in PubMed database at http://www.ncbi.nlm.nih.gov/pubmed/12087658 (1 page).
International Search Report for PCT/US2010/037374, dated Sep. 3, 2010, 3 pages.
Written Opinion for PCT/US2010/037374, dated Sep. 3, 2010, 7 pages.
Related Publications (1)
Number Date Country
20090204123 A1 Aug 2009 US
Provisional Applications (1)
Number Date Country
61026805 Feb 2008 US